Duyuru • Aug 12
Align Technology Prevails In China Patent Infringement Action Against Angelalign Align Technology Inc. announced that the Jinan Intermediate People's Court in China issued a judgment in favor of Align in a patent infringement action against Angelalign Technology's operating subsidiaries in China. In September 2025, Align filed a patent infringement action against Angel in the Jinan Intermediate People's Court, asserting Align’s patent related to extraction-gap-closure technology (CN113693748B). On August 10, 2026, the Jinan Intermediate People's Court issued a first-instance judgment finding that Angel's use of its MasterForce biomechanical simulation system and ATreat digital orthodontic treatment design system to generate A7 and A7 Speed premolar extraction treatment solutions infringes Align's patent rights. The court further found that the related aligner products manufactured and sold using the accused technology also infringe Align's patent. Angel may appeal the judgment to the Supreme People's Court. The deadline for filing an appeal has not yet expired. The court ordered Angel to cease using the patented technology and to stop manufacturing and selling the infringing products in China and awarded Align RMB 10 million in damages. The ruling remains subject to appeal. The ruling follows other recent developments in Align's patent-enforcement actions against Angel. In February 2026, the Unified Patent Court issued a preliminary injunction requiring Angel to cease infringement of Align's patented ClinCheck Live Update technology, a decision that was subsequently upheld on appeal. In July 2026, the U.S. International Trade Commission conducted an evidentiary hearing concerning five patents asserted by Align against Angel. Align expects that the ITC will make its initial determination regarding the merits of Align’s claims in November 2026. Align also continues to pursue additional patent infringement actions against Angel affiliates in China and Europe. Valuation Update With 7 Day Price Move • Aug 04
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to €10.30, the stock trades at a forward P/E ratio of 61x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total returns to shareholders of 71% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €9.30 per share. Duyuru • Jul 08
Angelalign Technology Inc. Launches Iortho Release 6.2 With New CBCT Visualization, Trimline Flexibility, And Redesigned Prescription Form Angelalign Technology Inc. launched iOrtho Release 6.2 with new improvements in CBCT visualization, new trimline flexibility and a redesigned Rx form. The release puts real clinical advances directly in doctors' hands, from fuller CBCT visualization featuring new 3D diagnostic views, to multiple trimline options, to a redesigned Rx for Primary and Refinement cases, alongside a set of optimizations that sharpen the tools doctors rely on day to day. Release 6.2 reflects Angel Aligner's continued investment in giving orthodontists the tools to treat with confidence. New improvements in CBCT Visualization: IRS (Intelligent Root System) Gold provides detailed 3D visualizations of cortical and cancellous bone, maxillary sinus, and airway structures for more comprehensive case evaluation. Updated color mapping also makes it easier to distinguish tissue types at-a-glance, helping doctors evaluate anatomical structures more efficiently during case review. Variable Trimline in Rx: For the first time, three trimline options — Standard (scalloped), Full-Arch High, and High at Posterior Teeth Only — are built directly into the Rx form, giving doctors more control at the prescription stage, before setup even starts. There's flexibility after the fact too: doctors can downgrade their trimline selection directly in iOrtho at approval, and upgrade from Posterior Only to Full-Arch on their own. Redesigned Prescription Form for Primary and Refinement Cases: For both Primary and Refinement cases, the prescription form is being redesigned for all users to give doctors more clinical control right at the point of prescription. Building on existing Rx capabilities, the updated form expands what doctors can specify at the prescription stage, giving them more clinical control before setup even begins. Refreshed Treatment Plan Interface: The 3D user interface has been redesigned to make planning faster and more intuitive. The 3D modification tools (Tooth, Features, Arch, Occlusal Plane) now sit in the top-right of the 3D view, so doctors can access and switch between them more easily. This helps doctors evaluate treatment options more efficiently and with greater confidence. Additional Improvements From Doctor Feedback: Beyond the major features, Release 6.2 includes several smaller improvements that came directly from doctor feedback. Each update addresses a specific request raised by orthodontists using the platform. iOrtho Release 6.2 went live July 1. New Risk • Jun 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (257% cash payout ratio). Share price has been volatile over the past 3 months (8.5% average weekly change). Significant insider selling over the past 3 months (€18m sold). Declared Dividend • May 20
Final dividend of HK$5.47 announced Shareholders will receive a dividend of HK$5.47. Ex-date: 21st May 2026 Payment date: 8th June 2026 Dividend yield will be 63%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (37% earnings payout ratio) but not covered by cash flows (257% cash payout ratio). The dividend has increased by an average of 106% per year over the past 3 years. However, payments have been volatile during that time. EPS is expected to grow by 105% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Duyuru • May 14
Angelalign Technology Inc. Applauds European Court Rejection of Patent Infringement Claim Angelalign Technology Inc. said it was grateful that the Local Division Düsseldorf (Germany) of the Unified Patent Court rejected a request by Align Technology Inc. (ALGN) for Angel to cease and desist from using its A7 Premolar Extraction Solution. Angel denied that the A7 tooth movement protocol infringes any patents as alleged by Align Technology Inc. (ALGN). The court rejected Align’s request for Angel to preliminarily cease its use of the feature, a decision Angel applauded. Duyuru • Mar 29
Angelalign Technology Inc. Proposes Special Dividend for the Financial Year End December 31, 2025, Payable on June 8, 2026 Angelalign Technology Inc. proposed special dividend of HKD 4.99 per share for the financial year end 31 December 2025. Date of shareholders' approval 19 May 2026, Ex-dividend date 21 May 2026, Record date 28 May 2026 and Payment date 08 June 2026. Duyuru • Feb 25
Angelalign Technology Inc. to Report Fiscal Year 2025 Results on Mar 27, 2026 Angelalign Technology Inc. announced that they will report fiscal year 2025 results on Mar 27, 2026 Duyuru • Feb 13
Align Technology Inc. Announces Preliminary European Court Ruling on Certain Software Features Will Have Minimal Impact on Users Angelalign Technology Inc. said a ruling by the Unified Patent Court of Dusseldorf, Germany that it preliminarily cease its use of certain software functions that automatically update treatment plans would have minimal impact on the orthodontists and patients who use its clear aligner products. The ruling applies to certain European countries and excludes Spain, Switzerland, United Kingdom and Ireland. Angel will launch iPlan for applicable European users, which is an upgrade feature that has the same reliability and more flexibility for users. Angel denied that the Live Now feature in its iOrtho treatment planning software infringes any valid patents of Align Technology Inc. (ALGN). Angel has already filed an opposition against the patent with the European Patent Office (EPO), asserting that the claimed invention is neither novel nor inventive over the prior art, and is seeking its permanent invalidation. Angel is confident it will overcome the first- instance, non-final and preliminary injunction issued by the Dusseldorf court. For many years, Angel has focused on developing innovative solutions in the clear-aligner segment. Among its cutting-edge products are the award-winning angelButton, the angelHook, the A6 mandibular advancement system (now celebrating its ten-year anniversary), the angel KiD system, and the Intelligent Root System. The company is committed to bringing fair and healthy competition to the marketplace to benefit doctors and their patients. Duyuru • Sep 25
Angelalign Technologies Remains Confident in Light of Its Competitor's New Complaint and Diversion Tactic Angelalign Technology Inc. remained confident in its position in light of the fact that industry behemoth Align Technology Inc. (ALGN) has filed another meritless case against Angel, this time with the U.S. International Trade Commission. This is the latest in a barrage of lawsuits launched by Align. Angel promises an effective defense and is confident that it will prevail. The company has innovated and operated for over 20 years with a strong reputation and track record of respecting intellectual property. Angel serves doctors and patients in 60 countries and regularly receives industry-leading satisfaction ratings. Angel has proudly led the clear-aligner field in innovation for many years while also recognizing Align's founding role in creating the industry years ago. Some examples of Angel's cutting-edge products are: The angelButton™ and the angelHook™, which allow orthodontists to manage forces effectively when using elastics. The A6 mandibular advancement system, which implements the twin-block orthodontic concept for doctors to move the mandible. AngelKid, a leading system to treat mixed dentition for young patients. Intelligent Root System, which allows orthodontists to use 3D imaging for treatment planning. Duyuru • Aug 19
Align Technology Initiates Patent Infringement Ligitation Against Angelalign Technology Align Technology Inc. announced the filing of patent infringement lawsuits against Angelalign Technology Inc. (Angel). The lawsuits allege that Angel’s products and associated software infringe Align patents, which encompass innovations such as multilayer aligner materials, cutting-edge treatment planning, and advanced aligner features. These legal actions have been initiated in the United States, Europe and China, jurisdictions where Align has made significant investments in innovation, aligner fabrication and treatment planning. Align seeks both injunctive relief and monetary damages through these intellectual property enforcement efforts. Duyuru • Aug 09
Angelalign Technology Inc. to Report First Half, 2025 Results on Aug 25, 2025 Angelalign Technology Inc. announced that they will report first half, 2025 results on Aug 25, 2025 Duyuru • Mar 20
Angelalign Technology Inc. Proposes Special Final Dividend for the Year Ended 31 December 2024, Payable on 20 June 2025 Angelalign Technology Inc. proposed special final dividend of HKD 0.38 per share for the year ended 31 December 2024. Date of shareholders' approval is 23 May 2025. Ex-dividend date is 27 May 2025. Record date is 2 June 2025. Payment date is 20 June 2025. Duyuru • Mar 05
Angelalign Technology Inc. to Report Fiscal Year 2024 Results on Mar 20, 2025 Angelalign Technology Inc. announced that they will report fiscal year 2024 results on Mar 20, 2025